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ABSTRACT 
Basic-region leucine-zipper transcription factors (bZIPs) contain a segment rich in basic 
amino acids that can bind DNA, followed by a leucine zipper that can interact with other leucine 
zippers to form coiled-coil homo- or heterodimers. Several viruses encode proteins containing 
bZIP domains, including four that encode bZIPs lacking significant homology to any human 
protein. We investigated the interaction specificity of these four viral bZIPs by using coiled-coil 
arrays to assess self-associations as well as hetero-interactions with 33 representative human 
bZIPs. The arrays recapitulated reported viral-human interactions and also uncovered new 
associations. MEQ and HBZ interacted with multiple human partners and had unique interaction 
profiles compared to any human bZIPs, whereas K-bZIP and BZLF1 displayed homo-specificity. 
New interactions detected included HBZ with MAFB, MAFG, ATF2, CEBPG, and CREBZF, 
and MEQ with NFIL3. These were confirmed in solution using circular dichroism. HBZ can 
hetero-associate with MAFB and MAFG in the presence of MARE-site DNA, and this 
interaction is dependent on the basic region of HBZ. NFIL3 and MEQ have different yet 
overlapping DNA-binding specificities and can form a heterocomplex with DNA. Computational 
design considering both affinity for MEQ and specificity with respect to other undesired bZIP-
type interactions was used to generate a MEQ dimerization inhibitor. This peptide, anti-MEQ, 
bound MEQ both stably and specifically, as assayed using coiled-coil arrays and circular 
dichroism in solution. Anti-MEQ also inhibited MEQ binding to DNA. These studies can guide 
further investigation of the function of viral and human bZIP complexes.   
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Many viruses hijack cellular machinery by using viral proteins to interact with host 
proteins. Viruses can incorporate host protein domains into their genomes for this purpose, as is 
the case for several viruses that use BCL-2 homologs to prevent apoptosis. Viral host-derived 
protein domains often make interactions similar to those of their homologues, although these can 
occur in a misregulated manner (1). Alternatively, host-derived protein domains can diverge 
from their cellular counterparts, such that they retain little sequence similarity. In such cases, 
virus-host protein interactions can be expected to differ markedly from corresponding host-host 
complexes (2).  
The bZIP transcription factors are a large class of proteins found in most eukaryotic 
organisms. Named for their DNA-binding and dimerization domain, bZIP proteins interact with 
DNA site-specifically via a region of conserved basic amino acids. Immediately C-terminal to 
the basic region is the leucine zipper, a coiled coil that mediates the formation of homodimeric or 
heterodimeric complexes. The dimerization specificity of the leucine zippers allows for 
combinatorial interactions that can influence DNA binding and thus transcriptional regulation (3, 
4). Given the importance of protein partnering specificity for the function of the bZIPs, a high-
throughput protein array assay was used to determine the global in vitro interaction profiles of 
most human bZIPs. The coiled-coil microarray assay used for this purpose was shown to identify 
most reported interactions, and the relative stabilities of interactions measured on the arrays were 
also shown to agree well with solution measurements (5, 6). 
Proteins containing bZIP domains have been identified in several viruses. Three human 
bZIP proteins, JUN (cJun), FOS (cFos), and MAF (cMaf), occur in an altered form in oncogenic 
avian and murine retroviruses. These homologous viral bZIPs maintain the protein dimerization 
properties of the human proteins and are oncogenic because of altered regulation (7-9). Four 
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viral bZIPs that have little homology to human bZIPs have also been identified, and although 
several interactions with host proteins have been reported, global investigation of the interactions 
of these proteins with host bZIPs is lacking. 
Human T-cell leukemia virus type 1 is a retrovirus that causes adult T-cell leukemia; it 
encodes the bZIP protein HBZ (reviewed in (10)). HBZ has been shown to repress both viral and 
cellular gene expression. A recent study suggests that in addition to the role of the HBZ protein 
in disease progression, the mRNA of HBZ promotes proliferation (11). Interactions have been 
reported between HBZ and many human bZIPs both in vivo and in vitro including ATF4, JUN, 
JUNB, JUND, CREB1, and ATF1 (12-15). HBZ has been shown to form complexes with JUN, 
JUNB, CREB1, and ATF4 and to prevent these proteins from binding DNA. In contrast, HBZ 
has been reported to increase the transcriptional activity of JUND (13).   
MEQ is encoded by Marek's disease virus (MDV), an oncogenic herpes virus that infects 
chickens. The disease is estimated to cost the US poultry industry one billion dollars annually 
(reviewed in (16)). MEQ has been demonstrated to be largely responsible for the oncogenic 
properties of MDV (17-19). MEQ can self-associate as well as interact with a variety of other 
bZIPs in vitro including: JUN, JUNB, CREB1, ATF1, ATF2, ATF3, FOS, and BATF3 (17, 20-
22). Additionally, MEQ has been shown to bind JUN in vivo, and JUN is required for MEQ to 
transform cells (18, 20).  
Two gammaherpesviruses are reported to encode bZIP-containing proteins. These viruses 
are implicated in several proliferative disorders in humans. Epstein-Barr virus encodes BZLF1 
(ZEBRA, Zta, Z, EB1) and is associated with Burkitt’s lymphoma, Hodgkin’s disease, and 
nasopharyngeal carcinoma. Kaposi’s sarcoma-associated herpesvirus encodes K-bZIP (K8, RAP) 
and is involved in Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s 
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disease (reviewed in (23, 24)). These two proteins are positional homologs and also share low 
sequence similarity with one another (25). BZLF1 is responsible for triggering the switch from 
latent to lytic infection by binding sites within the viral genome and causing transcriptional 
activation of many genes. It is also involved in viral replication (26, 27). Over-expression of K-
bZIP does not cause virus reactivation, but K-bZIP is necessary for viral replication as well as 
the repression and activation of many genes within the viral genome, though not always through 
direct binding to promoters (28, 29). BZLF1 and K-bZIP both interact with many viral and 
cellular proteins including the human bZIP CEBPA (C/EBPα) (30). Interestingly, the interaction 
with CEBPA for both BZLF1 and K-bZIP is proposed to involve higher order oligomers rather 
than just dimers (31, 32). Recently, the crystal structure of BZLF1 was solved showing that a C-
terminal region adjacent to the leucine zipper folds back and stabilizes the coiled-coil structure, 
significantly stabilizing the homodimer (33). K-bZIP has been shown to self associate through its 
leucine zipper, but this homomeric interaction was reported to be one of higher order oligomers 
(25, 32).  
Given the importance of both human and viral bZIPs to human health, several strategies 
have been used to generate inhibitors that can prevent dimerization and/or DNA binding. One 
approach is to use the leucine zipper of a homodimerizing bZIP as a dominant negative. The 
utility of this approach has been demonstrated in the context of BZLF1. Using a peptide that 
consisted of only the leucine zipper of BZLF1, (34) Hicks et al. showed that BZLF1 could be 
prevented from binding DNA. However, the EC50 for the peptide was high micromolar. A 
possible disadvantage of using native leucine-zipper peptides as inhibitors is that these may 
associate with bZIPs other than the desired target. Recently, we reported a computational design 
method for obtaining peptides that interact specifically with leucine zippers and applied it to a 
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range of human targets. Out of the 20 human bZIP families, peptides were designed that 
successfully interacted with 19. Of these 19, 8 designs bound to their target family stronger than 
to any other family (5). 
Here we report all pair-wise interactions of four bZIP peptides derived from viral proteins 
with 33 human bZIP proteins measured using peptide microarrays. We identified several new 
interactions for both MEQ and HBZ, and these interactions were confirmed using circular 
dichroism and gel-shift assays. Additionally, we designed a peptide, anti-MEQ, to serve as a 
MEQ dimerization inhibitor. We demonstrate that this peptide binds specifically to MEQ and can 
prevent MEQ from binding DNA.   
 
EXPERIMENTAL METHODS 
Plasmid construction, protein expression and purification- Human protein constructs used for 
array experiments have been previously described and are listed in Table S1 (5, 6). Synthetic 
genes encoding the leucine zipper regions of HBZ, MEQ, BZLF1, K-bZIP, anti-MEQ and the 
full bZIP domains of MAFB, HBZ, and MEQ were synthesized using DNAWorks to design 
primers and a two-step PCR method to anneal them (35). The bZIP domains of CREBZF, ATF2 
and JUND were cloned from plasmids acquired from Open Biosystems (36) and NFIL3, JUN, 
CEBPG and MAFG were cloned from plasmids obtained from PlasmID (37).These proteins 
were cloned into modified versions of a pDEST17 vector. Proteins were expressed in RP3098 
cells and purified under denaturing conditions using Ni-NTA followed by reverse-phase HPLC 
as described previously (5, 6). A tagless version of anti-MEQ used for gel-shift and CD studies 
was constructed by cloning into pSV282 (Vanderbilt University Medical Center, Center for 
Structural Biology). The 6XHIS-MBP-anti-MEQ fusion protein was expressed in RP3098 cells 
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by growing a 1 L culture in LB at 37 °C and inducing at 0.5 OD by adding 1 mM IPTG and 
growing for 4 hours. The fusion protein was purified under native conditions by binding to Ni-
NTA resin (Qiagen) and eluted by adding 8 ml buffer (300 mM imidazole, 20 mM TRIS, 500 
mM NaCl, 1 mM DTT, pH 7.9). The fusion protein was then dialyzed overnight into TEV 
cleavage buffer (50 mM TRIS, 50 mM NaCl, 1 mM DTT, 0.5 mM EDTA, pH 7.5) and then 
cleaved by adding 100 µl TEV protease (1mg/ml) for 3 hours at 18-22 °C. This mixture was then 
added to Ni-NTA resin and the flow-through collected. The anti-MEQ peptide was further 
purified using reverse-phase HPLC. The molecular weights of the peptides were confirmed by 
mass spectrometry. Protein sequences generated for this study are listed in Table S1. 
Coiled-coil arrays- Array experiments were performed as described previously (5). The average 
background-corrected fluorescence values for all measurements are listed in Table S2. Two 
measures used to report fluorescence intensities in the figures are Sarray and arrayscore. These are 
defined in references (5) and (38), respectively. Sarray   was calculated using the equation  
array
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where a was the of the average fluorescence intensity of each 
protein on the surface and ã was the median signal for all proteins on the surface that interact 
with the same solution protein, N was the number of proteins on the surface, and Na<ã was the 
number of proteins with a value a below the median. The arrayscore values were calculated 
using the equation –log(F/Fmax) where F was the value of the average fluorescence intensities of 
each protein on the surface minus the median signal for all proteins on the surface interacting 
with the same solution protein and Fmax was the maximum F. 
Circular dichroism- Circular dichroism experiments were performed as described previously (5). 
ãThe concentrations used for each experiment are listed in the figure legends. Thermal 
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dentaturations were measured from 0 to 65 °C and all were reversible with all complexes having 
differences in Tm of less than 3 °C upon refolding. The buffer for CD measurements of MEQ 
was PBS (potassium phosphate (pH 7.4) and 150 mM KCl) with 1mM DTT. For measurements 
of HBZ the buffer also included 200 mM GdnHCl and 0.25 mM EDTA. 
Phylogenetic analysis- An unrooted phylogenetic tree was constructed using the neighbor-
joining method for the 53 human and 4 viral bZIP leucine-zipper regions as described previously 
(5). For comparison of chicken and human sequences, each human bZIP was used to BLAST the 
G. gallus genome and 41 chicken bZIPs were identified. Leucine-zipper regions were defined as 
previously reported (6). Families were defined according to evolutionary conservation and 
interaction profiles, as in (6, 39). 
Gel-shift assay- DNA probes for the AP-1, TFIID, and NF-κB sites were obtained from 
Promega. Other probes were based on literature-defined sequences (MARE (40), CAAT (41), 
CRE1 (20), CRE2 (42), MDVORI (20)), ordered as PAGE-purified oligos (IDT) and then 
annealed. Probes were end labeled with [γ-32P]ATP using PNK (NEB). Proteins were incubated 
for 3 hours at 18-22 °C in gel-shift buffer (50 mM KCl, 25 mM TRIS pH 8.0, 0.5 mM EDTA, 
2.5 mM DTT, 1 mg/ml BSA, 10% (v/v) glycerol, 0.1 mg/ml competitor DNA (Poly (I)·Poly (C) 
(GE)). Radiolabeled DNA was then added and incubated for 1 hour at 18-22 °C. Radiolabeled 
DNA was at a final concentration of 0.7 nM, except for experiments in Figure S4 where the final 
concentration was 20 nM. Protein/DNA mixtures were loaded on NOVEX DNA retardation gels 
(Invitrogen) using 0.5X TBE buffer and run at 200-300V for 15-25 minutes. For complexes 
involving JUN proteins, the buffer was pre-cooled to 4 °C to prevent complex dissociation. Gels 
were dried and imaged using a phosphorimaging screen and a Typhoon 9400 imaging system. 
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Computational design of anti-MEQ- Anti-MEQ was designed using CLASSY with the HP/S/Ca 
energy function as previously reported (5). 46 human proteins and design homodimerization 
were used as negative design states. 
 
RESULTS 
Four unique bZIPs are encoded by viral genomes. There are four bZIPs of viral origin 
described in the literature that are not closely related to any human bZIP. These are MEQ, HBZ, 
BZLF1, and K-bZIP. To compare these proteins to the human bZIPs, a phylogenetic tree was 
constructed using the leucine-zipper regions of the four viral proteins as well as 53 human bZIPs 
(Figure 1A). According to this analysis, all four viral bZIPs are quite diverged from human 
bZIPs. The sequences of the 4 viral bZIPs are aligned to several representative human sequences 
in Figure 1B. Human bZIPs have a highly conserved basic region consisting of the motif 
(R/K)XX(R/K)N(R/K)XAAXX(S/C)RX(R/K)(R/K) (43), and a striking feature of the basic-
region alignment is the presence of an invariant asparagine in almost all human bZIPs. The only 
two human families that do not have this asparagine are CREBZF (ZF, Zhangfei) and DDIT3 
(CHOP), which are not known to bind DNA as homodimers but can bind as heterodimers (44, 
45). An arginine, separated by 8 residues from the conserved asparagine, is strictly conserved in 
all human bZIPs. Both MEQ and BZLF1 conform well to this conserved motif and include the 
key asparagine and arginine residues. In contrast, the basic regions from HBZ and K-bZIP poorly 
match the basic-region motif, and neither contains the key conserved asparagine or arginine. The 
leucine-zipper regions of human bZIPs are 4-7 heptads long and are characterized by strong 
conservation of leucine every 7 amino acids. MEQ, HBZ, and to a lesser extent K-bZIP, have 
mostly canonical leucine-zipper regions. On the other hand, BZLF1 has a very short leucine 
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zipper that is non-canonical, with only one coiled-coil d-position leucine (coiled-coil residues are 
traditionally labeled a-f, with a and d largely buried in the core, e and g on the periphery and b, c 
and f on the outside of the helical complex). BZLF1 has also been shown to be stabilized by an 
extended C-terminal region that makes contacts with the coiled coil (33). These observations are 
consistent with reports of both MEQ and BZLF1 binding DNA, whereas there is no direct 
evidence to support binding of DNA by HBZ (20, 33, 46). K-bZIP has been shown to directly 
bind DNA, though it is not clear whether the bZIP domain is involved (47).  
Unlike HBZ, K-bZIP and BZLF1, which are found in viruses that infect humans, MEQ is 
encoded by an avian oncovirus. Because of the availability of a large number of human, but not 
avian, bZIP clones, we wanted to confirm that human bZIPs could be used as a reasonable 
substitute for chicken bZIPs. MEQ has been previously reported to interact with both human and 
mouse bZIP proteins (20). We also compared human bZIP sequences to chicken bZIP sequences 
and found them to be highly homologous (Figure S1). Considering just the coiled-coil interface 
positions that are most responsible for interactions (adeg), 85% of direct orthologues have 
greater than 90% identity. Additionally, all human bZIP families are conserved between human 
and chicken, except DDIT3, which is specific to humans.  
Detection of viral-human bZIP interactions. Interactions between human and viral bZIPs 
were measured using a previously described protein microarray assay (5, 6). The leucine-zipper 
regions of 33 representative human bZIPs were purified and printed onto aldehyde-derivatized 
glass slides along with leucine zippers from the 4 viral proteins (Table S1). All human bZIP 
families were represented on the arrays except for OASISb, which is very similar in its protein 
sequences and interaction profiles to OASIS. Each protein was then individually fluorescently 
labeled and used to probe the arrays at a concentration of ~160 nM, unless otherwise indicated. 
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A total of 8 spots on the surface were used for each measurement. The fluorescence intensity of 
each spot was corrected for background, and the averages of the 8 values were converted into a 
score called Sarray, a Z-score like measure, as described previously (Table S2) (5).  
As in prior studies using this technique, there were several indications that the data are of 
good quality. First, interactions observed among human bZIPs (measured simultaneously with 
the viral-human interaction data) were highly consistent with previously published data (Figure 
S2)(6). Next, each heteromeric interaction was measured twice, once when the first protein was 
on the surface and again when it was in solution. Most interactions were observed in both 
directions. Further, interactions involving MEQ and HBZ were measured over a large range of 
concentrations and gave rise to similar interaction profiles (Figure 2B). Finally, many 
interactions observed between viral and human proteins were consistent with prior reports, as 
discussed below. 
Most previously reported interactions involving the viral bZIPs were observed on the 
array and are indicated by green boxes in Figure 2A. Exceptions are boxed with green dotted 
lines in Figure 2A and include the interaction of HBZ with ATF4 and the interaction of MEQ 
with FOS. However, the HBZ—ATF4 interaction was reported to be weaker with just the 
leucine-zipper region (as was measured on the arrays) than in context of the entire protein (15). 
Also, the interaction of MEQ with FOS has been shown to be weak compared to other 
interactions of MEQ (17, 20). Several interactions previously reported to not occur were also not 
observed to interact on the arrays. These include HBZ self interaction, HBZ—FOS, BZLF1—
FOS, and BZLF1—JUN (14, 48, 49). Both BZLF1 and K-bZIP have been reported to interact 
with CEBPA, but not as heterodimers (see Discussion). 
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Many previously unreported interactions were detected for HBZ. New partners included: 
MAF and MAFB, MAFG, ATF2 and ATF7, CEBPG (C/EBPγ), CREBZF, and ATF3. MEQ was 
found to interact with NFIL3 (E4BP4) and BACH1. Meq was also found to interact with JUND 
and ATF7, members of the JUN and ATF2 families that MEQ is known to interact with. 
Interactions were also observed for MEQ with DDIT3 and NFE2, but these proteins are not 
conserved between human and chickens. DDIT3 is a member of the one human bZIP family that 
is not found in chickens. The NFE2 family is conserved in chickens but the human NFE2 protein 
does not have a direct ortholog, and the member of the family that does have a conserved 
ortholog, NFE2L1, is not observed to interact with MEQ.  
BZLF1 was observed to self-associate strongly, but not to interact with any human bZIP 
peptides (Figure 2A). A BZLF1 construct with the C-terminal extension (BZLF1CT) also did not 
interact strongly with any human proteins. This construct gave greater fluorescence signal when 
probed against itself than against the version containing just the leucine zipper. BZFL1CT also 
showed strong signal at a lower concentration than BZLF1 with just the leucine zipper. This 
result is consistent with previous reports documenting stabilities in solution, and further 
demonstrates the ability of the arrays to accurately report relative affinities (Figure S3)(34, 50). 
K-bZIP interacted with itself stronger than with any other protein on the arrays. Weak 
interactions were observed with ATF2 and ATF7 when K-bZIP was in solution, but these 
interactions were not observed when K-bZIP was on the surface (Figure 2A).   
A significant result of this experiment is that the leucine-zipper regions of MEQ and HBZ 
participate in multiple interactions with different human bZIPs, while BZLF1 and K-bZIP 
display almost exclusive homo-association (Figure 2A). Additionally, MEQ and HBZ each 
interact with a unique combination of partners (Figure 2C). HBZ interacts with many of the same 
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proteins as ATF3 and FOS, but is distinguished by many other strong interactions that are not 
made by these proteins, including interactions with both the small and large MAF families, 
CEBPG, and CREBZF. MEQ also has a similar profile to human ATF3 and FOS, but 
additionally interacts strongly with NFIL3. 
Validation of novel interactions of HBZ and MEQ in solution. To validate novel 
interactions detected on the protein microarrays we tested associations using circular dichroism 
(CD). Proteins consisting of the bZIP domain (basic region plus leucine zipper) were used for 
these experiments (see Methods, Table S1). For NFIL3, the chicken and human proteins are 
identical in this region. For the MAF proteins, the extended homology region that contains an 
auxiliary DNA binding domain was included (51). We first tested JUN for interaction with HBZ 
and MEQ. JUN has been reported to interact with both MEQ and HBZ and was also observed to 
interact with both on the arrays. HBZ and Jun each at 40 µM were mixed together and the CD 
spectrum was measured (Figure 3A). Spectra were also recorded for each protein in isolation. 
The spectra of each individual protein, as well as the mixture, had minima at 208 and 222 nm, 
which is characteristic of coiled coils. The observed mean residue ellipticity at 222 nm ([θ]222) is 
consistent with the expected helical content for these peptides forming coiled coils, as the leucine 
zipper accounts for ~50% of the sequence (52). The mixture also had increased signal compared 
to the sum of the individual proteins, indicating a hetero-association. Similar results were 
observed for MEQ and JUN (Figure 3B). 
We next tested HBZ against the newly identified partners ATF2, CEBPG, CREBZF, 
MAFG, and MAFB. Thermal melts monitored by CD were performed with each protein at a 
concentration of 4 µM and the mixture at 8 µM. Thermal melts were also carried out for HBZ 
with JUN (Figure 3, C-H). Over a large range in temperature, all mixtures had increased signal 
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over the sum of the spectra for the individual proteins, confirming the interactions. We then 
performed thermal melts of MEQ with NFIL3 and with JUN (Figure 3I, J). Again the mixture 
had increased signal over that expected for non-interacting proteins. Two pairs not observed to 
interact on the arrays, HBZ with NFIL3 and MEQ with MAFB, also were not observed to 
interact in solution (Figure 3K, L). Thus, all protein pairs tested in solution agreed well with the 
results of the protein array assay. 
Characterization of HBZ interactions with human proteins in the presence of DNA. We 
tested whether HBZ could prevent its human bZIP interaction partners from binding DNA and/or 
whether heteromeric HBZ complexes could themselves bind DNA. MAFB and MAFG were 
tested in a gel-shift assay using a MARE site (40). Both bound MARE DNA as homodimers at a 
concentration of 4 nM, but HBZ did not bind even at a 100-fold higher concentration. 
Surprisingly, when highly purified HBZ at increasing concentrations was mixed with a constant 
concentration of either highly purified MAFB or MAFG, an additional shifted band of greater 
mobility appeared (Figure 4A). We inferred that this band included both HBZ and MAFB or 
MAFG. To determine whether formation of this complex was dependant on the basic region of 
HBZ, a leucine-zipper-only version of HBZ, HBZLZ, was mixed with the MAF proteins. The 
amount of MAF protein bound to DNA was decreased, though a higher concentration of HBZLZ 
was required. No additional complex was detected (Figure 4B). This is the first evidence, to our 
knowledge, that HBZ can directly bind to DNA, and that this binding depends on the basic 
region. The stoichiometry and structure of the observed heterocomplex remain unknown. We 
also tested whether ATF2 or CEBPG could bind DNA in complex with HBZ. Both ATF2 and 
CEBPG at 20 nM were prevented from binding MARE DNA by HBZ, but no additional band 
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was formed (Figure 4C). CREBZF was not tested in complex with HBZ on DNA as CREBZF is 
not known to bind DNA by itself (44). 
MAFG also binds to the AP-1 site and was tested for binding in combination with HBZ. 
In contrast to the MARE site, HBZ decreased the binding of MAFG to the AP-1 site without 
formation of any additional shifted bands (Figure 4D). Both the AP-1 and the MARE sites 
contain the core consensus binding site TGA(C/G)TCA. The MAF proteins have an auxiliary 
binding domain that is responsible for binding flanking residues of the MARE site (51). At the 
middle of the binding site, position 0, the MARE site we used has a C and the AP-1 site contains 
a G. To determine if this middle position can affect DNA binding by HBZ:MAFG complexes, 
the 0 position in MARE was changed to a G and the same position in AP-1 was changed to a C. 
The mutant sites had similar binding properties to unchanged sites, suggesting that the middle 
position is not the key element that influences HBZ—MAFG heteroassociation on AP-1 vs. 
MARE (Figure 4E, F). This suggests that bases flanking the core site are important for HBZ 
binding.   
Characterization of MEQ and NFIL3 binding to DNA. To determine whether NFIL3 and 
MEQ could bind DNA as heterodimers we tested several known bZIP-binding sites. AP-1, also 
known as TRE, is a site bound by JUN and by FOS-JUN heterodimer (53). CAAT contains the 
consensus site for the CEBP family of bZIPs (54). CRE1 and CRE2 are two CRE-like sites that 
have been previously used in DNA binding studies with MEQ and NFIL3 and are each one 
change away from the consensus CRE site TGACGTCA (20, 42). Also tested was the MDVORI 
site, which is derived from the origin of replication of Marek’s disease virus. MEQ has 
previously been shown to bind this site as a homodimer (20). In a gel-shift assay neither MEQ 
nor NFIL3 bound strongly to the negative control sites TFIID or NF-κB at 80 nM. Only MEQ 
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bound strongly to the AP-1 site and only NFIL3 bound strongly to the CAAT site. Both MEQ 
and NFIL3 bound the CRE1 and CRE2 sites, though NFIL3 bound more strongly. For both of 
these sites there appeared to be some heterodimer formation, but the predominant species was 
the NFIL3 homodimer. Interestingly, NFIL3 bound to the MDVORI site, but weaker than MEQ 
did. The mixture on the MDVORI site was composed of primarily MEQ homodimers (Figure 
5A).   
We also wanted to know if MEQ and NFIL3 could bind a DNA site predominantly as a 
heterodimer. Previously it has been shown that heterodimer sites can be constructed by taking 
consensus half-sites for each of two interacting bZIPs (55). A DNA site was constructed that 
contains the consensus half-sites for MEQ (ACAC) and NFIL3 (GTAA), referred to in Figure 5C 
and below as MEQ/NFIL3 (20, 56). This site has only two changes from the MDVORI site, at 
positions +1 and +3. This hybrid site was bound as a homodimer by both MEQ and NFIL3. 
NFIL3 bound tighter than MEQ, and when both proteins were mixed, the predominant species 
bound to the site was the heterocomplex, with mobility between the two homodimers (Figure 
5A).  
The MDVORI probe used in Figure 5 was 30 base pairs long, and to further probe the 
nature of a MEQ—NFIL3 interaction we tested whether NFIL3 bound at a similar location as 
MEQ. Competition gel-shift experiments were performed to test this. MEQ and NFIL3 were 
individually incubated with radiolabeled MDVORI site and with cold competitor DNA encoding 
either the MDVORI site or a variant of it. Single-base substitutions were made at 10 consecutive 
positions in the site. Additionally, 2 double substitutions and a triple-mutant site were 
constructed. Changes that affected MEQ binding by at least 2-fold were localized toward the 5’ 
half of the MDVORI site (Figure 5B). Substitutions that weakened MEQ binding included -4C, -
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3A, and -1A. The change of -2T strengthened MEQ binding. The double mutant of -3A:-1A 
decreased binding more than either individual substitution. NFIL3 binding was decreased by the 
changes -1A, +1C, +2G, and +4C. The substitutions -3A and +3A increased binding of NFIL3. 
Combining -2T and +1C decreased binding further. The changes of -1A and +2G decreased 
binding individually, but when both were together in combination with -3A, the triple mutant had 
no decrease in binding (Figure 5B). These 13 altered sites were also tested for direct binding to 
MEQ and NFIL3 and the results were consistent with the competition binding experiments 
(Figure S4). Additionally, significant heterodimer formation by MEQ and NFIL3 was observed 
on the +3A site, consistent with results using the hybrid site in Figure 5A (Figure S4). Several 
things are apparent from this experiment. First, mutations on the 5’ side of the site affect binding 
to MEQ, while those toward the 3’ end, and at the last two positions of the left half-site, affect 
binding to NFIL3. Second, most DNA base changes have differential effects on the binding of 
MEQ and NFIL3, demonstrating they indeed have different binding specificities. Third, MEQ 
and NFIL3 bind at a similar location on the MDVORI DNA site.  
Generation of a specific inhibitor of MEQ dimerization. Specific inhibitors of bZIP 
interactions could provide valuable tools for elucidating function and could potentially serve to 
validate transcription factors as therapeutic targets. To generate a specific peptide to bind MEQ, 
that could potentially act as a dominant-negative inhibitor, we used a recently published 
computational design method called CLASSY (5). CLASSY was used to automatically design a 
peptide sequence predicted to bind MEQ but to have minimal binding to any human bZIP or to 
itself. The designed 42-residue anti-MEQ peptide was tested for its ability to bind MEQ using 
bZIP protein arrays including anti-MEQ, MEQ, and a panel of 32 human bZIPs (these included 
all the human peptides tested previously except DDIT3, which is specific to humans). Anti-MEQ 
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bound MEQ stronger than any human protein (Figure 6A). The other proteins that anti-MEQ 
bound strongest are the ATF2 family proteins ATF2 and ATF7, followed by JUN and BATF3. 
Even at the highest concentration tested, 2000 nM, anti-MEQ bound MEQ and the ATF2 family 
proteins preferentially to other bZIPs. Anti-MEQ was not observed to interact with itself on the 
arrays. These results demonstrate that anti-MEQ is specific for binding to MEQ.  
To compare the stability of the anti-MEQ—MEQ complex with that of other MEQ 
interactions, we probed MEQ against an array including MEQ, anti-MEQ, and the panel of 32 
human peptides. MEQ interacted with anti-MEQ as strongly as it interacted with JUN, which 
was MEQ’s strongest interaction partner observed on the array (Figure 6A). The three strongest 
off-target interactions, ATF2, JUN, and BATF3, were also tested in solution against anti-MEQ. 
ATF2 bound anti-MEQ strongly compared to its strongest interactions on the array. In contrast, 
JUN and BATF had much weaker interactions with anti-MEQ. Overall these results suggest that 
anti-MEQ has high affinity for, and is specific for, interaction with MEQ. 
The interaction of MEQ and anti-MEQ in solution was studied using a tag-less version of 
anti-MEQ (see Methods). CD spectra showed that anti-MEQ is mostly unfolded at 40 µM, and 
when combined with 40 µM MEQ the mixture has more signal than either MEQ or anti-MEQ 
alone, indicating an interaction. The mixture also has a spectrum characteristic of a coiled coil 
(Figure 6B). Thermal melts of anti-MEQ mixed with both MEQ and ATF2 were performed at 4 
µM of each protein and 8 µM total protein for the mixture (Figure 6C, D). The temperature of 
half denaturation (Tm) for anti-MEQ was 12.8 °C, for MEQ was 35.2 °C, and for ATF2 was 36.7 
°C. The Tm for anti-MEQ in complex with MEQ was 40.5 °C, and thus the hetero-association is 
more stable than either the homo-association of MEQ or anti-MEQ. The Tm of ATF2 in complex 
with MEQ was 31.8 °C. JUN, a strong interaction partner for MEQ, has a Tm in complex with 
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MEQ of 41.3 °C. These results are consistent with the array data. A helical wheel diagram 
depicting the predicted interaction geometry of MEQ and anti-MEQ is shown in Figure 6E. The 
design has leucine residues at 5 consecutive d-positions, imparting stability to the complex (57). 
It also introduces a complementary asparagine residue to interact with an asparagine at an a-
position in MEQ; this interaction is known to favor parallel dimer formation (58). The e- and g-
positions of anti-MEQ are complementary to those in MEQ, and two rather uncommon cysteine 
residues at a positions are predicted to lie across from designed alanine and lysine residues. 
Lysine at core a positions also favors dimer formation (59). Two lysines at a positions are 
complementary to glutamate residues at g position on the opposite helix. These a-g’ interactions 
have previously been shown to make important contributions to specificity (5, 38).  
To test whether anti-MEQ could prevent MEQ from binding DNA, 20 nM MEQ was 
incubated with increasing amounts of anti-MEQ and then radiolabeled MDVORI DNA was 
added to the reactions. Anti-MEQ prevented MEQ binding of DNA, with an IC50 of less than 500 
nM (Figure 7A). Binding of MEQ to AP-1 DNA was also inhibited by anti-MEQ (data not 
shown). The experiment was repeated with 20 nM JUN and the AP-1 DNA site. No decrease in 
JUN binding was observed even at 12.5 µM anti-MEQ (Figure 7B). The strongest off-target 
interaction for anti-MEQ, ATF2, was also tested. At 20 nM ATF2 no decrease in binding was 
observed when incubated with anti-MEQ (Figure 7C). At 4 nM ATF2, anti-MEQ decreased 
ATF2 binding, but at higher concentrations than required for preventing MEQ binding (Figure 
7D). These results show that anti-MEQ can prevent MEQ from binding DNA at a lower 
concentration than it inhibits its strongest off-target interaction. 
 
DISCUSSION 
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The bZIP transcription factors function by forming homodimers or heterodimers with 
other bZIP proteins. In this context, viruses use bZIP proteins in a number of distinct ways that 
are illuminated by the systematic study we present here. Several viral bZIPs that have high 
sequence identity to host homologues maintain the interaction patterns of the host bZIPs. 
Examples include v-FOS, v-JUN, and v-MAF (7-9). The viral bZIPs HBZ and MEQ are not 
closely related to any other bZIPs, and they have distinct interaction profiles compared to the 
human bZIPs. K-bZIP and BZLF1 are also not highly conserved, but these two viral proteins 
primarily self-associate.  
For MEQ and HBZ, we have uncovered new interactions that suggest possible 
mechanisms of action of these proteins. The mechanism of HBZ protein function has been 
somewhat of a mystery. The non-canonical basic region of this protein argues against direct 
DNA binding, yet HBZ was shown previously to have a strong activation domain, suggesting 
that it might function to regulate transcription when complexed with human bZIP proteins and 
DNA (15, 60). Additionally, HBZ has been shown to stimulate the transcriptional activity of 
JUND(13). However, data so far have not supported a direct interaction of HBZ itself with DNA. 
Here we present the first evidence that HBZ can directly bind DNA. HBZ can bind a MARE 
DNA site with MAFB or MAFG. This binding of DNA is specific and is dependent both on the 
HBZ basic region and on DNA that flanks the central binding site. While most bZIPs bind a 4-5 
base pair half site, different flanking regions around an AP-1 site have previously been shown to 
have different affinities for binding to JUN/FOS heterodimers (61). The HBZ ternary complex 
that we observed on DNA with either MAFB or MAFG was weaker than MAF—DNA 
complexes. Also the HBZ—MAF complexes occurred at higher concentrations of HBZ relative 
to MAF protein. Because the sequence of the HBZ basic region is unique, it may have a distinct 
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DNA-binding specificity, and it remains a possibility that higher affinity sites for HBZ in 
association with MAF proteins exist.  
The MAF proteins belong to two classes: the four large MAF proteins, which contain a 
transcriptional activation domain, and the three small MAF proteins that don’t. The small MAFs 
interact with the NFE2 and BACH families of bZIPs and play a major role in the response to 
oxidative stress (62). The large MAF proteins are similar to the JUN proteins in that both are 
involved in cell growth and proliferation, both are proto-oncogenes and can cause cellular 
transformation, and both have retroviral homologues (63, 64). They also have been reported to 
share similar downstream targets in inducing cellular transformation (65). 
Other proteins we confirmed to interact with HBZ in vitro are CEBPG, ATF2, and ZF. 
The CEBP family of bZIPs is involved in cell growth and differentiation. CEBPG forms 
heterodimers with CEBP family proteins to repress their transcriptional activity (66). ATF2 has 
been shown to stimulate JUN-mediated cellular transformation (67). CREBZF was identified as 
having a role in herpes simplex virus gene expression (68). CREBZF also interacts with ATF4, a 
known partner of HBZ (15, 44). With ATF2 and CEBPG, it remains to be seen whether HBZ 
heterodimers can bind DNA sites, or if HBZ functions primarily by preventing binding of these 
partners to target sites. Neither HBZ nor CREBZF have been shown to bind DNA as 
homodimers, suggesting that they have intrinsically weaker affinities for DNA and together 
would not be likely to bind DNA as a heterodimer. These newly reported partners, along with 
other known partners, suggest that HBZ has the potential to impact several different 
transcriptional pathways. 
It was recently shown that MEQ homodimers alone are not sufficient to induce 
transformation, suggesting that heterodimer formation with other bZIPs is necessary (17). JUN 
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has been shown to be an important MEQ partner, required for cellular transformation mediated 
by MEQ, but it is likely that other interaction partners are also functionally important. Here we 
identified a previously unreported bZIP partner, NFIL3, and showed that it can form 
heterodimers with MEQ on DNA. NFIL3 was first identified as a transcriptional repressor that 
bound the adenovirus E4 promoter, and was later shown to have an activating role associated 
with anti-apoptotic activity. NFIL3 is also involved in regulating circadian rhythms (56, 69, 70). 
NFIL3 was further shown in the hepatitis B virus to both repress viral gene expression as well as 
viral replication (71). In this context, it is interesting that NFIL3 can bind to the MDVORI site as 
a homodimer. The MDVORI site from the origin of replication of MDV is also situated between 
a bidirectional promoter that MEQ has been shown to repress as a homodimer (20, 21). There 
may exist functionally significant sites that MEQ and NFIL3 can bind as a heterodimer with 
greater affinity than either homodimer. It will be important to determine what role NFIL3 has on 
the MDV life cycle, both alone and in combination with MEQ.  
Other novel interactions with bZIP families detected on the arrays but not tested further 
are HBZ with ATF3, and MEQ with BACH1. Based on the intensity of the fluorescence signal, 
these interactions are likely to be weaker than the other interactions tested, but they may be 
significant. Also, numerous interactions that we did not assay are highly likely to occur involving 
paralogs of the proteins tested here. Although these interactions need to be confirmed 
experimentally, most bZIP paralogs are highly similar to each other and have been shown to 
share similar interaction profiles (5, 6, 39).  
An interesting result is that the leucine-zipper regions of BZLF1 and K-bZIP 
preferentially self-associate. Both proteins are reported to interact with CEBPA, but this pairing 
was not observed in our array experiments. Basic residues were required for this interaction in 
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the case of BZLF1, and both proteins were observed to interact with CEBPA as higher-order 
multimers and not as heterodimers (31, 32). Our observation that the leucine zippers are not 
sufficient for these interactions is consistent with those studies. It is not surprising, given the 
unique structure of BZLF1, that it does not form canonical interactions with human BZIPs.  
MDV is the first oncogenic virus for which a vaccine was made available to control the 
disease, but increasing viral resistance is becoming a real concern to the poultry industry. 
Further, MDV has proven valuable as a model oncogenic virus, and deletion and knockdown 
experiments have demonstrated the necessity of MEQ for oncogenic transformation (18). It has 
also been reported that a virus encoding a MEQ protein that cannot form homodimers or 
heterodimers has a complete loss of oncogenicity, suggesting that the function of MEQ could be 
inhibited by preventing MEQ from interacting with bZIPs (19). We showed that a 
computationally designed anti-MEQ peptide can prevent MEQ from binding DNA in a specific 
manner, indicating that anti-MEQ could be a useful reagent for studying the role of MEQ on the 
oncogenic properties of MDV. If necessary to achieve higher affinity, the anti-MEQ peptide 
could potentially be further stabilized through the addition of an acidic peptide extension that 
interacts with the basic region, as has been demonstrated for numerous other coiled coils by the 
Vinson laboratory (41). 
In summary, we have shown that coiled-coil arrays are a powerful method for broadly 
surveying the interaction properties of viral bZIP dimerization domains. Comprehensive testing 
for in vitro interactions with all human bZIP families is an important step in exploring the 
functions of these proteins. Further, we have validated that several newly discovered viral-host 
complexes can bind to DNA, suggesting a mechanism by which viruses hijack cellular 
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transcriptional control. Determining which of the bZIPs that can associate in vitro also interact 
with functional consequences in vivo will be an important next step. 
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 FIGURE LEGENDS 
Figure 1. Sequence properties of human and viral bZIPs. (A) A phylogenetic tree was inferred by 
neighbor-joining using only the leucine-zipper region of each of the 53 human bZIPs and the 4 
viral bZIPs. Viral sequences are boxed. Proteins used to measure interactions are indicated with a 
black square. Family names are in bold. The scale bar refers to amino-acid changes per position. 
(B) Multiple-sequence alignment of viral bZIPs with representative human bZIPs. The following 
are underlined: Highly conserved basic-region asparagine and arginine residues and conserved 
leucines in the leucine zippers. 
 
Figure 2. Identification of viral bZIP interactions using peptide microarrays. Interactions are 
displayed as a color map, as indicated by the scale at right. Family names are listed in the first 
column and individual proteins are listed in the second column. (A) Interactions made by 4 viral 
proteins, when in solution or on the surface, are shown in columns. The potential interaction 
partners are in rows. Each heteromeric interaction is shown twice, corresponding to the two 
different ways it could be measured. Observations in agreement with prior studies are boxed in 
green; those interactions reported to be weak in the literature are indicated with dashed boxes. 
Fluorescently labeled proteins were used at 160 nM in a phosphate buffer that included 1M 
guanidine hydrochloride (GdnHCl), except BZLF1 was used at a probe concentration of 1280 
nM and K-bZIP was used at a probe concentration of 640 nM in 2.2 M GdnHCl. (B) MEQ and 
HBZ interactions at concentrations of 1-1800 nM. (C) Interaction profiles for 6 human proteins 
used as solution probes are shown for comparison to HBZ and MEQ solution profiles.   
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Figure 3.  Solution measurements of novel interactions for HBZ and MEQ. 
(A and B) CD spectra at 40 µM for each protein or 80 µM for each mixture at 25 °C. (A) HBZ 
(open triangles), JUN (open circles), mixture (dashed line). (B) MEQ (open triangles), JUN 
(open circles), mixture (dashed line). (C-J) Thermal melts monitored by CD at 4 µM for each 
protein or 8 µM for each mixture. All mixtures are shown in dashed lines. (C) HBZ (open 
triangles), JUN (open circles). (D) HBZ (open triangle), MAFB (open circles). (E) HBZ (open 
triangles), MAFG (open circles). (F) HBZ (open triangles), ATF2 (open circles). (G) HBZ (open 
triangles), CEBPG (open circles). (H) HBZ (open triangles), CREBZF (open circles). (I) MEQ 
(open triangles), JUN (open circles). (J) MEQ (open triangles), E4BP4 (open circles). (K) HBZ 
(open triangles), NIFL3 (open circles). (L) MEQ (open triangles), MAFB (open circles). 
 
Figure 4. Binding of HBZ and human bZIPs to specific DNA sites assessed by gel-shifts. Homo- 
and hetero- complexes formed on DNA are indicated. (A) HBZ can form heterocomplexes with 
MAFB or MAFG on MARE DNA sites. The concentration of MAFB was 4 nM, MAFG was 4 
nM, and HBZ was 4, 40 or 400 nM. (B) A leucine-zipper-only version of HBZ (HBZLZ) 
prevents MAFB and MAFG from binding MARE-site DNA. The concentration of MAFB was 4 
nM, MAFG was 4 nM, and HBZLZ was at 4, 40, 400, or 4000 nM. HBZLZ incubated alone was 
at 4000 nM. (C) HBZ prevents ATF2 and CEBPG from binding MARE-site DNA. The 
concentrations of ATF2 and CEBPG were 20 nM, and HBZ was at 40 or 400 nM. (D) HBZ 
prevents MAFG from binding AP-1 DNA. The concentration of MAFG was 20 nM, and HBZ 
was at 40 or 400 nM. (E) AP-1-site variant TGACTCA (G0C) was not sufficient for HBZ to bind 
DNA with MAFG. The concentration of MAFG was 20 nM with AP-1 G0C and 4 nM with 
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MARE C0G. The concentration of HBZ was 40 or 400 nM. (F) DNA sequences used in gel-shift 
assays; the consensus site is underlined and position 0 is indicated. 
 
Figure 5. MEQ and NFIL3 interact and have different but overlapping DNA-binding 
specificities. (A) Gel-shift experiments with MEQ and NFIL3. The concentration of MEQ and 
NFIL3 was 80 nM each or 160 nM total protein for mixtures. Each homodimer and heterodimer 
is indicated. (B) Competition gel-shift demonstrates that MEQ and NFIL3 bind to similar regions 
of an MDV probe, but have differing specificities. Each protein was at 80 nM incubated with 0.7 
nM radiolabeled MDVORI DNA. Above each lane is listed the mutation or mutations made in 
cold competitor DNA (400 nM). Three individual experiments were quantified, and those 
positions that gave ≥ 2-fold changes are indicated (+/- indicate increase/decrease in binding). (C) 
DNA sequences used in gel-shift assays; the consensus site is underlined. The positions of the 
MDV site are numbered.  
  
Figure 6. Anti-MEQ binds MEQ with high affinity and specificity. (A) Designed peptide anti-
MEQ characterized using coiled-coil arrays. Color map of arrayscore is shown, with the colors 
defined in the scale. Left, anti-MEQ at different concentrations (nM) in solution is listed in 
columns, with proteins printed on the surface in rows. Right, MEQ and 3 human bZIPs tested 
against anti-MEQ and other proteins printed on the surface. (B) CD spectra at 40 µM for each 
protein or 80 µM for the mixture taken at 25 °C. MEQ (open triangles), anti-MEQ (open circles), 
and the mixture (dashed line). (C and D) Thermal melts monitored by CD at 4 µM for each 
protein or 8 µM for the mixture. (C) MEQ (open triangles), anti-MEQ (open circles), and the 
mixture (dashed line). (D)ATF2 (open triangles), anti-MEQ (open circles), and the mixture 
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(dashed line). (E) Helical wheel diagram predicted for the interaction of MEQ with anti-MEQ. 
The complex is depicted as a parallel dimer, and the two helices of the coiled coil are shown 
from the N-terminus, with the sequence read clockwise and outwards on each helix. Coiled-coil 
heptad positions are labeled. Hydrophobic residues are in black, charged residues are in red/blue, 
and polar residues are in green. Potential attractive electrostatic interactions are shown in dashed 
blue lines. Diagram created using DrawCoil 1.0. (http://www.gevorggrigoryan.com/drawcoil/). 
 
Figure 7. Anti-MEQ prevents MEQ from binding DNA. Competition gel-shifts with a constant 
amount of the indicated protein bound to DNA were titrated with increasing amounts of anti-
MEQ. Concentrations of competitor peptide were 0.02, 0.1, 0.5, 2.5, and 12.5 µM. Labeled DNA 
was present at 0.7nM. (A) 20 nM MEQ with MDVORI DNA. (B) 20 nM JUN with AP-1 DNA. 
(C) 20 nM ATF2 with CRE2 DNA. (D) 4 nM ATF2 with CRE2 DNA. 
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SUPPLEMENTARY FIGURE LEGENDS 
Figure S1. Comparison of Human and Chicken bZIPs. Tree is inferred by neighbor-joining using 
the leucine-zipper sequence of each human bZIP and each G. galus bZIP as described in the 
methods. Human sequences are in black and chicken sequences are in green. Family names are 
listed in purple. The scale bar refers to amino-acid changes per position. Overall, the chicken 
sequences are highly homologous to the human sequences, as judged by the short branch lengths 
between orthologs. All families are conserved between chicken and human, except for DDIT3, 
which is human specific. 
 
Figure S2. Complete interaction matrix of 33 human bZIPs and 4 viral bZIPs. Data are displayed 
as in Figure 2. Solution probe proteins are in columns, and proteins on the surface are in rows.  
 
Figure S3. Neither the BZLF1 leucine zipper nor BZLF1 with additional C-terminal residues 
binds strongly to any human bZIP.  Fluorescently labeled BZLF1 at 1280 nM and BZLF1 with 
the C-terminal region (BZLF1CT) at 160 nM in solution are listed in columns and potential 
partners on the surface are listed in rows. Data are displayed as in Figure 2.  
 
Figure S4. Gel shifts showing MEQ and NFIL3 directly binding to variants of the MDV DNA 
site. (A) DNA sequences used in gel-shift assays. The putative binding site is underlined. (B) Gel-
shift experiments with MEQ and NFIL3 binding to different DNA sites. The concentration of 
MEQ and NFIL3 was 80 nM each or 160 nM total protein for mixtures. Each lane had 20 nM 
radiolabeled DNA. Each homodimer, heterodimer, and free probe is indicated at left. Strong 
heterodimer formation is observed on the +3A site.  
SUPPLEMENTARY TABLES 
Table S1.  Protein sequences used in this study. 
Table S2. Average background-corrected fluorescence values from the array experiments. 




Identification of bZIP interaction partners of viral proteins HBZ, MEQ, BZLF1, and K-bZIP using coiled-coil arrays
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Table S1.  Protein sequences used in this study. Linker region of proteins is in bold.
Proteins used in array studies 
Name Protein Source
CEBPA
SYYHHHHHHLESTSLYKKAGSGSQRNVETQQKV
LELTSDNDRLRKRVEQLSRELDTLRGIFRQLLE 1
CEBPB
SYYHHHHHHLESTSLYKKAGSEFSDEYKIRRERN
NIAVRKSRDKAKMRNLETQHKVLELTAENERLQK
KVEQLSRELSTLRNLFKQLPEPLLASSGHC
1
CEBPD
SYYHHHHHHLESTSLYKKAGSGSRRNQEMQQKL
VELSAENEKLHQRVEQLTRDLAGLRQFFKQL LE 1
CEBPG
SYYHHHHHHLESTSLYKKAGSEFGERNNMAVKK
SRLKSKQKAQDTLQRVNQLKEENERLEAKIKLLTK
ELSVLKDLFLEHAHNLADNVQSISTENTTADGLE
1
DDIT3
SYYHHHHHHLESTSLYKKAGSEFRMKEKEQENE
RKVAQLAEENERLKQEIERLTREVEATRRALIDRM
VNLHQA
1
ATF1
SYYHHHHHHLESTSLYKKAGSEFDPQLKREIRLM
KNREAARECRRKKKEYVKCLENRVAVLENQNKTL
IEELKTLKDLYSNKSV
1
CREB1
SYYHHHHHHLESTSLYKKAGSGSKEAARKREVR
LMKNREAARECRRKKKEYVKCLENRVAVLENQN
KTLIEELKALKDLYCHKSD
1
CREB3L3
SYYHHHHHHLESTSLYKKAGSGSEYIDGLETRMS
ACTAQNQELQRKVLHLEKQNLSLLEQLKKLQAIVV
QSTSLE
1
CREB3
SYYHHHHHHLESTSLYKKAGSEFWRRKIRNKRS
AQESRRKKKVYVGGLESRVLKYTAQNMELQNKV
QLLEEQNLSLLDQLRKLQAMVIEISNKTSSRLE
1
ATF6
SYYHHHHHHLESTSLYKKAGSEFACQSRKKKKE
YMLGLEARLKAALSENEQLKKENGTLKRQLDEVV
SENQRLKVPSPKRRVLE
1
CREBZF
SYYHHHHHHLESTSLYKKAGSEFCRLNRLKKKEY
VMGLESRVRGLAAENQELRAENRELGKRVQALQ
EESRYLRAVLANETGLE
1
XBP1
SYYHHHHHHLESTSLYKKAGSEFQTARDRKKAR
MSELEQQVVDLEEENQKLLLENQLLREKTHGLVV
ENQELRQRLGMDALVAEEEAEAKGNEVLE
1
HLF
SYYHHHHHHLESTSLYKKAGSGRLKENQIAIRAS
FLEKENSALRQEVADLRKELGKCKNILAKYEARH L 1
NFIL3
SYYHHHHHHLESTSLYKKAGSEFEKRRLNDLVLE
NKLIALGEENATLKAELLSLKLKFGLISSTAYAQEIQ
KLSNSTAVYFQDYQTSKSNVLE
1
ATF2
SYYHHHHHHLESTSLYKKAGSEFDLERNRAAAS
RCRQKRKVWVQSLEKKAEDLSSLNGQLQSEVTL
LRNEVAQLKQLLLAHKDCPVTAMQKKSGFLE
1
ATF7
SYYHHHHHHLESTSLYKKAGSEFKRKLWVSSLE
KKAEELTSQNIQLSNEVTLLRNEVAQLKQLLLAHK
DCPVTALQKLE
1
JUN
SYYHHHHHHLESTSLYKKAGSGSRKLERIARLEE
KVKTLKAQNSELASTANMLREQVAQLKQKVMNHL
E
2
JUNB
SYYHHHHHHLESTSLYKKAGSGSRKLERIARLED
KVKTLKAENAGLSSTAGLLREQVAQLKQKVMNHL
E
2
JUND
SYYHHHHHHLESTSLYKKAGSGSRKLERISRLEE
KVKTLKSQNTELASTASLLREQVAQLKQKVMNHL
E
2
ATF3
SYYHHHHHHLESTSLYKKAGSGSCPEEDERKKR
RRERNKIAAAKCRNKKKEKTECLQKESEKLESVN
AELKAQIEELKNEKQHLIYMLNLHRPTCIVRAQNG
RTPEDLE
1
ATF4
SYYHHHHHHLESTSLYKKAGSEFNKTAATRYRQK
KRAEQEALTGECKELEKKNEALKERADSLAKEIQY
LKDLIEEVRKARGKKRVP
1
ATF5
SYYHHHHHHLESTSLYKKAGSEFNRKQKKRDQN
KSAALRYRQRKRAEGEALEGECQGLEARNRELK
ERAESVEREIQYVKDLLIEVYKARSQRTRSC
1
FOS
SYYHHHHHHLESTSLYKKAGSEFFRRERNKMAA
AKCRNRRRELTDTLQAETDQLEDEKSALQTEIANL
LKEKEKLEFILAAHRPACKIPDDLGFPEEMS LE
1
FOSL2
SYYHHHHHHLESTSLYKKAGSEFERNKLAAAKC
RNRRRELTEKLQAETEELEEEKSGLQKEIAELQKE
KEKLEFMLVAHGPVCKISPLE
1
BATF
SYYHHHHHHLESTSLYKKAGSGSQKADTLHLESE
DLEKQNAALRKEIKQLTEELKYFTSVLNSHELE 1
BATF3
SYYHHHHHHLESTSLYKKAGSEFRSRKKQTQKA
DKLHEEYESLEQENTMLRREIGKLTEELKHLTEAL
KEHEKMCPLLLCPMNFVHLE
1
MAFG
SYYHHHHHHLESTSLYKKAGSEFGVTQKEELEK
QKAELQQEVEKLASENASMKLELDALRSKYEALQ
TFARTVARSPVAPARGPLAAGLGPLVPGKVAATS
VITIVKSKTDALE
1
MAF
SYYHHHHHHLESTSLYKKAGSEFQRVQQRHVLE
SEKNQLLQQVDHLKQEISRLVRERDAYKEKYEKL
VSSGFRENGSSSDNPSSPEFFM
1
MAFB
SYYHHHHHHLESTSLYKKAGSEFQYKRVQQKHH
LENEKTQLIQQVEQLKQEVSRLARERDAYKVKCE
KLANSGFREAGSTSDSPSSPEFFL
1
NFE2
SYYHHHHHHLESTSLYKKAGSEFQRKLETIVQLE
RELERLTNERERLLRARGEADRTLEVMRQQLTEL
YRDIFQHLRDESGNS
1
NFE2L1
SYYHHHHHHLESTSLYKKAGSEFKLDTILNLERDV
EDLQRDKARLLREKVEFLRSLRQMKQKVQSLYQE
VFGRLRDENGRPYYLEII
1
NFE2L3
SYYHHHHHHLESTSLYKKAGSEFGDIRRRGKNKV
AAQNCRKRKLDIILNLEDDVCNLQAKKETLKREQA
QCNKAINIMKQKLHDLYHDIFSRLRDDQGRPVLE
1
BACH1
SYYHHHHHHLESTSLYKKAGSEFGCRKRKLDCIQ
NLESEIEKLQSEKESLLKERDHILSTLGETKQNLTG
LCQKVCKEAALSQEQNLE
1
HBZ
SYYHHHHHHLESTSLYKKAGSGSMQELGIDGYT
RQLEGEVESLEAERRKLLQEKEDLMGEVNYWQG
RLEAMWLQ
This study
MEQ
SYYHHHHHHLESTSLYKKAGSGSDYVDKLHEAC
EELQRANEHLRKEIRDLRTECTSLRVQLARHEP This study
BZLF1
SYYHHHHHHLESTSLYKKAGSGSAKFKQLLQHY
REVAAAKSSENDRLRLLLKQMGGRDYKDDDDK This study
K-bZIP
SYYHHHHHHLESTSLYKKAGSGSVSSKAYTRQL
QQALEEKDAQLCFLAARLEAHKEQIIFLRDMLMRM
CQQGGRDYKDDDDK
This study
BZLF1CT
SYYHHHHHHLESTSLYKKAGSGSAKFKQLLQHY
REVVAAKSSENDRLRLLLKQMCPSLDVDSIIPRTP
DVLHEDLLNFLE
This study
anti-Meq
SYYHHHHHHLESTSLYKKAGSGSNLLATLRSTAA
VLENENHVLEKEKEKLRKEKEQLLNKLEAYK This study
Proteins used in circular dichroism and gel-shift studies
Name Protein Source
JUN
SHHHHHHGESKEYKKGSGSSPIDMESQERIKAE
RKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQN
SELASTANMLREQVAQLKQKVMNH
This study
CEBPG
SHHHHHHGESKEYKKGSGSKKSSPMDRNSDEY
RQRRERNNMAVKKSRLKSKQKAQDTLQRVNQLK
EENERLEAKIKLLTKELSVLKDLFLEHAHNLAD  
This study
CREBZF
SHHHHHHGESKEYKKGSGSGGGSGNDNNQAAT
KSPRKAAAAAARLNRLKKKEYVMGLESRVRGLAA
ENQELRAENRELGKRVQALQEESRYLRAVLANET
GL
This study
MAFB
SHHHHHHGESKEYKKGSGSSDDQLVSMSVRELN
RHLRGFTKDEVIRLKQKRRTLKNRGYAQSCRYKR
VQQKHHLENEKTQLIQQVEQLKQEVSRLARERDA
YKVKCEKLANSG
This study
MAFG
SHHHHHHGESKEYKKGSGSTDEELVTMSVRELN
QHLRGLSKEEIVQLKQRRRTLKNRGYAASCRVKR
VTQKEELEKQKAELQQEVEKLASENASMKLELDA
LRSKYEALQTFARTVARS
This study
NFIL3
SHHHHHHGESKEYKKGSGSREFIPDEKKDAMYW
EKRRKNNEAAKRSREKRRLNDLVLENKLIALGEE
NATLKAELLSLKLKFGLIS
This study
ATF2
SHHHHHHGESKEYKKGSGSRRRAANEDPDEKR
RKFLERNRAAASRCRQKRKVWVQSLEKKAEDLS
SLNGQLQSEVTLLRNEVAQLKQLLLAHKDC
This study
HBZ
SHHHHHHGESKEYKKGSGSKAADVARRKQEEQ
ERRERKWRQGAEKAKQHSARKEKMQELGIDGYT
RQLEGEVESLEAERRKLLQEKEDLMGEVNYWQG
RLEAMWLQ
This study
MEQ
SHHHHHHGESKEYKKGSGSDGLSEEEKQKLERR
RKRNRDAARRRRRKQTDYVDKLHEACEELQRAN
EHLRKEIRDLRTECTSLRVQLARHEP
This study
HBZLZ
SHHHHHHGESKEYKKGSGSMQELGIDGYTRQLE
GEVESLEAERRKLLQEKEDLMGEVNYWQGRLEA
MWLQ
This study
anti-Meq
GSNLLATLRSTAAVLENENHVLEKEKEKLRKEKE
QLLNKLEAYK This study
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Table S2.  Average background corrected values from the array experiments. Peptides in solution are in columns and those on the surface are in rows. Concentrations are in nM.
CEBPA CEBPB CEBPD CEBPG DDIT3 ATF1 CREB1 CREB3L3 CREB3 ATF6 CREBZF XBP1 HLF NFIL3 ATF2 ATF7 JUN JUNB JUND FOS FOSL2 ATF3 ATF4 ATF5 BATF BATF3 MAFG MAF MAFB NFE2 NFE2L1 NFE2L3 BACH1 HBZ MEQ BZLF1 K-bZIP
CEBPA 16400.2 8465.3 27862.6 9709.6 15186.7 -506.3 -1345.1 39.0 854.9 447.3 -2210.8 602.6 721.7 311.0 177.7 2142.6 443.3 161.8 167.2 1028.4 123.3 1594.4 10297.5 1135.1 1670.0 7982.9 -575.3 -934.9 -293.4 -638.4 1073.9 -148.1 -368.5 1309.2 -708.9 -783.2 562.8
CEBPB 7461.5 4130.7 8591.9 7753.9 26228.3 -908.5 -1663.9 -241.4 -715.6 625.3 -2029.1 1612.2 811.4 -975.4 -242.9 2616.4 131.1 411.6 -31.4 -336.8 176.7 2371.0 4304.3 215.2 3457.9 7326.8 -133.1 -727.9 105.6 -1147.5 -1948.4 -577.6 -910.1 -477.9 -298.4 -1051.2 625.0
CEBPD 19228.3 10494.0 24816.0 13870.9 15487.3 -704.8 -1884.8 -909.6 3206.9 141.8 -3693.8 -82.5 2449.6 -42.6 -1858.2 -205.4 -22.1 -468.6 -785.9 142.3 220.8 2765.6 13044.8 699.1 3465.8 14516.9 -297.1 -2206.0 -2014.8 -694.6 -242.4 -359.5 -1313.5 -1656.9 516.5 -2122.3 109.3
CEBPG 8962.2 7403.8 27789.5 1671.9 13620.6 -174.0 542.7 -861.8 4113.4 1245.2 -1881.1 1262.3 4043.1 1323.0 3834.6 7042.0 109.3 585.5 478.8 337.8 958.9 12723.0 18182.6 15097.3 8235.8 13138.5 173.1 -852.9 231.3 -1149.2 -1961.5 -111.7 -702.4 12122.4 -628.9 -1955.2 644.0
DDIT3 26600.9 20762.0 38960.3 32663.2 4609.1 602.1 1200.6 1171.1 9313.8 1412.0 1187.1 1250.8 39900.9 9541.1 8325.1 10043.6 1175.8 2991.4 2757.3 9237.4 4533.2 15455.3 8893.6 -417.9 28971.3 28594.8 1536.8 -1347.8 611.0 -417.8 -1159.9 -529.6 3344.6 2995.1 11570.3 -1620.2 1211.4
ATF1 -2325.3 -752.7 -3890.6 -1944.6 -1049.1 7323.9 10884.8 -2272.6 -2677.4 540.4 -1896.8 2023.9 -631.4 3741.3 -1573.1 -700.9 -126.0 190.1 -350.2 -999.0 -169.2 -1237.6 -414.1 -246.6 -614.0 -1975.0 -104.4 -359.8 88.1 -1059.5 -1537.7 -694.8 1387.8 1919.3 1229.4 -952.4 470.0
CREB1 -4412.3 -1331.3 -5543.4 -3011.3 -1302.8 12318.6 16312.6 8183.3 22.6 -1502.1 -5257.4 1707.9 -2266.8 3658.4 -5291.3 -1166.6 -782.3 -780.0 -1985.9 -2004.8 -770.9 -2966.8 -1935.2 -1794.8 -827.1 -5137.0 -2140.3 -1584.5 -1828.8 -2132.1 -2342.7 -1817.6 1554.8 1390.1 308.1 -5005.3 -1437.0
CREB3L3 -2019.1 -547.3 -3228.1 -713.1 -1378.3 1139.9 2580.6 6710.3 10436.3 1545.3 -1101.1 1565.8 -1001.6 4204.5 -261.5 -371.4 -138.6 388.7 -376.4 28.5 -55.8 90.6 -360.2 340.1 -731.8 1616.0 -118.4 -1526.3 -162.1 -442.7 -1033.6 -145.8 -1069.3 -1271.8 -1173.2 -477.1 707.3
CREB3 40.0 75.4 387.8 -597.7 295.3 -503.5 -114.5 2829.3 4008.9 718.2 32.5 1099.8 170.5 57.3 -509.8 -516.1 87.5 -121.1 81.8 -581.9 -327.1 845.1 750.3 146.4 -573.1 3517.6 -11.4 -216.1 313.6 -403.4 -1329.1 -388.5 -680.3 -2641.1 -1215.8 -1004.0 1465.9
ATF6 -3547.4 -593.4 -3227.4 -1915.9 -1391.2 -298.7 -14.1 -503.3 -2670.7 9418.6 841.3 7659.4 -1641.3 -554.3 -2102.8 -1167.4 -720.4 -154.4 -564.4 -1550.1 -225.3 -1524.8 -427.6 -256.4 -860.6 -2381.9 -362.3 -3037.8 -1734.8 -1253.4 -5055.6 -1213.9 -1130.1 -3234.3 -1562.9 -1382.3 -253.3
CREBZF -2999.2 -615.9 -5579.0 -1615.1 -1600.5 -594.1 -947.2 -306.9 -2843.9 1969.0 17003.4 13108.1 -1889.5 218.9 -1429.3 632.1 468.1 1032.5 659.6 -202.6 72.6 -384.6 2317.1 -353.2 -950.6 1108.5 319.6 -456.8 785.6 3389.6 28134.8 -319.6 1476.9 22064.3 -311.6 -446.1 665.6
XBP1 -6916.5 -547.2 -7262.9 -2792.9 -3011.3 754.8 2224.9 -768.8 -3298.7 13998.1 19643.8 20740.2 -2661.9 -1162.3 -2233.0 -832.6 -171.3 458.9 236.1 -1021.7 -120.2 -1818.7 -990.6 -1059.9 -1572.4 -2693.0 -184.6 -2038.6 -1934.4 -1843.4 -3647.8 -660.7 -998.4 -3391.2 -2531.2 -932.7 -703.3
HLF -1301.0 256.9 -1111.6 -1468.2 2365.1 -154.1 -418.7 -161.4 -702.9 242.4 -75.2 1249.9 7040.4 710.3 -2027.1 -942.8 -291.2 597.9 -395.6 -1201.5 -259.3 -1568.9 307.9 -433.8 985.0 2552.6 -979.3 -1756.4 -2103.1 -760.1 -1636.1 -497.4 -143.3 -1102.4 -862.1 -303.6 96.2
NFIL3 -1599.6 74.3 -1199.6 -973.9 115.3 9223.2 13337.8 2318.7 8054.4 1508.5 -344.8 1191.6 1051.4 36187.8 -2371.1 -1067.3 -13.9 221.2 -460.8 -1433.9 -113.6 129.3 -314.7 -1169.5 -1087.4 3450.6 541.3 -1163.1 162.9 -1204.9 -2694.3 -336.3 119.2 -1272.2 23075.2 782.5 1249.1
ATF2 1035.3 392.1 -2091.9 5852.3 2062.8 -529.5 -146.8 -1034.7 -718.0 611.7 -534.2 1981.5 868.6 -2132.6 5073.2 5239.1 3518.8 3925.3 4649.3 5701.9 3343.9 7935.4 965.4 49.6 801.9 9572.6 296.9 403.2 1718.0 -658.4 2436.4 -564.0 3625.6 16538.5 23802.8 -927.8 3657.6
ATF7 3827.6 2387.9 1705.9 8493.0 5268.9 -286.3 221.4 -355.9 864.9 928.9 919.6 1260.1 1360.1 -536.4 6890.5 8203.3 8006.6 4837.2 7666.8 9036.9 6553.8 10295.4 2822.0 -847.1 511.3 11128.9 587.5 -452.3 734.8 1374.6 6706.9 -1.9 5311.4 28123.2 19304.9 -774.6 3157.4
JUN -1138.9 1104.1 1273.4 1133.4 1112.1 837.5 2531.1 -201.8 -41.4 912.5 -53.3 1307.4 4855.9 -169.6 19776.8 19617.1 2428.2 1385.8 1262.9 45551.8 28676.3 17605.2 -405.3 -571.8 26673.3 21878.4 -343.4 -127.4 422.3 -1870.0 -1487.1 -336.9 -122.0 48963.6 39542.5 -1311.6 188.0
JUNB 329.0 328.1 333.1 -1054.5 859.6 -143.9 299.9 -2793.0 -2083.4 1165.6 210.2 884.7 2361.5 -1109.3 5917.8 7557.8 393.0 270.0 356.9 29611.2 14296.9 8909.2 83.7 67.6 16984.4 19485.6 -801.1 15.2 344.4 -973.4 -2384.4 -387.2 225.1 40558.8 31224.1 -1748.8 21.7
JUND -534.6 384.4 853.2 17.3 -17.2 33.8 534.7 -959.6 -902.1 1144.2 19.0 1101.1 3347.6 -866.3 10644.5 13456.1 513.0 367.0 107.1 37736.6 19249.6 12655.8 -394.1 -294.9 22249.5 20503.4 -66.3 -1469.6 107.6 -1095.0 -1442.8 -381.0 -292.0 41619.3 35094.7 -1585.0 -153.9
FOS 3174.7 262.3 1517.2 2895.8 3169.9 729.7 1007.3 97.1 1038.8 718.4 1801.2 1088.4 996.4 522.0 8367.4 10322.2 20367.8 19903.6 22831.6 3277.1 1276.4 2225.3 3989.1 497.0 -607.3 1681.9 614.1 1296.3 7607.3 -800.9 5250.3 11.7 2734.4 -779.8 556.6 147.2 2752.4
FOSL2 -2308.9 -751.7 -4357.6 -2292.1 777.8 441.7 1460.4 -1100.6 -1721.3 1350.8 158.9 1436.9 516.9 -368.7 8843.4 8116.8 12360.6 13728.4 16881.4 3924.3 653.4 3644.9 715.6 -421.1 -2058.3 -918.3 308.5 -915.1 5471.6 -1209.8 581.1 -562.3 797.1 -1588.6 130.4 793.8 776.7
ATF3 2806.1 4267.3 2664.2 22753.4 9553.3 -106.5 -425.6 232.3 2208.9 1007.6 -972.4 2238.9 1037.1 704.1 12564.9 14134.1 6003.6 8068.3 8131.3 3642.9 2656.0 454.6 5220.8 -504.4 1485.6 22269.8 678.7 60.3 4383.3 -979.4 -1967.0 -1035.5 -74.9 5899.5 9460.0 -2718.6 -105.5
ATF4 42648.7 7702.9 31696.6 37828.5 16336.9 -293.9 -469.8 764.2 1426.9 -389.4 11897.4 721.7 4694.9 -1019.1 778.9 2882.3 -438.0 -336.2 -779.4 5731.6 588.9 5657.8 -837.6 -316.6 2929.7 11336.2 -221.5 6439.6 992.2 -332.4 19231.1 1636.9 104.1 -315.4 1530.2 -2728.5 1150.2
ATF5 7171.6 416.8 7273.9 37753.9 -1748.5 -1494.4 -3841.6 -1762.7 -2506.3 -907.9 -3414.4 124.6 1124.4 -1773.8 -3627.9 -2386.1 -1661.9 -1547.1 -2013.1 -2763.5 -372.4 -2583.8 -736.8 -1240.7 223.8 5578.3 -3506.4 -1479.8 -2058.9 151.6 -9.1 -1057.8 254.7 -2894.6 -2460.9 -4593.2 284.1
BATF 3553.1 4548.5 5470.9 15419.5 11096.2 755.9 2427.5 -81.2 5270.6 1826.2 722.6 1111.6 13375.9 2610.4 4101.5 2571.9 11045.4 17121.3 18955.2 12.6 -526.9 3272.2 2899.7 1919.1 -225.9 5890.9 279.3 -3082.1 697.3 -325.0 3975.8 277.4 2975.8 232.6 -1556.4 -379.3 1524.9
BATF3 2636.2 3614.8 9704.8 7478.2 15171.9 -562.1 278.1 787.2 9465.5 1012.4 1747.7 1144.1 12205.6 2602.0 6868.8 6773.6 9549.0 12115.1 11855.2 571.1 353.1 10329.4 3567.6 908.1 1052.8 9517.6 2334.0 -995.0 1245.4 -1131.8 14.5 -516.3 1450.1 956.3 7311.6 218.6 724.1
MAFG -1183.9 -63.0 -311.9 -622.7 1139.0 647.1 2002.4 -1726.7 1331.4 670.8 343.2 1756.7 159.6 1850.6 764.4 1274.1 949.8 1946.8 1579.7 1644.1 -170.9 624.0 578.6 565.2 -894.4 6731.1 4335.0 -1075.3 879.1 10390.6 40099.8 25157.4 23867.6 19230.9 2409.8 294.1 702.3
MAF -2329.4 -339.8 -4658.0 -1457.8 -1166.8 225.1 1056.9 -785.8 -1984.5 934.9 -1061.8 767.5 -1173.0 -805.8 -294.3 -868.0 -13.8 1040.6 473.6 512.9 50.8 -81.9 3239.0 -101.0 -1018.1 -1526.8 15.8 19582.3 15441.3 -978.3 3799.9 46.8 3977.6 31679.4 -967.6 -947.9 1099.2
MAFB -5483.4 -1013.9 -6333.9 -2140.1 -2616.7 221.3 1218.9 -920.0 -3630.9 915.3 705.4 1588.4 -1800.8 -629.3 -618.8 -975.2 -318.8 837.3 744.2 3415.9 1257.3 -81.8 -448.7 -735.3 -789.6 -1361.7 -558.1 18881.3 9776.6 -676.4 5247.4 -326.2 7328.3 24522.3 -2220.7 -235.6 1006.9
NFE2 -2821.6 -614.0 -4646.7 -1510.3 -920.4 -208.2 -396.0 -840.0 -545.9 1375.8 -576.6 1034.0 -2282.5 -783.9 -1479.1 -1312.3 -778.5 -422.6 -833.8 -1096.3 -216.4 -1347.9 188.1 -74.3 -1950.9 -2877.1 1434.5 -1266.4 21.4 18844.8 -1051.1 7592.4 -732.0 -2449.0 1464.1 -453.8 1604.1
NFE2L1 -2720.7 -1318.3 -2439.9 -4630.6 -3339.6 1320.4 3225.5 -1003.4 571.8 620.9 21919.8 790.6 428.9 -2427.6 345.8 1426.8 -1354.3 -264.5 -212.5 1023.4 282.4 -1609.1 3815.4 257.0 -1244.8 227.1 43009.4 453.8 2918.1 1124.9 4304.1 -92.3 -365.7 -1764.1 -1512.3 -788.9 1046.8
NFE2L3 -2135.3 -1394.6 -2950.1 -2078.8 -1473.6 -1587.1 -1765.9 -293.0 -1720.3 -930.3 -2797.8 216.3 -1946.4 -711.4 -3174.6 -1290.1 -1013.0 -980.9 -1452.3 -2584.0 -534.7 -2328.6 -128.6 -636.8 -897.5 -3180.9 52198.0 -959.1 -863.3 16419.4 -2762.6 37.6 -1337.8 -3129.1 -2098.4 -2208.9 -456.8
BACH1 -533.6 -139.6 -2345.4 946.1 415.6 3900.5 6874.6 -354.8 584.9 2954.9 3984.0 2655.3 2069.2 1005.3 4546.8 3102.4 245.8 1229.9 1290.2 2196.3 574.4 285.2 805.4 1171.4 367.3 3569.8 20474.3 6783.8 12128.5 -886.4 323.8 -273.4 2255.3 -4121.1 1847.1 1551.6 2643.2
HBZ -972.4 1002.1 1611.6 3554.8 677.3 17760.8 25708.1 -493.2 1685.6 3201.4 16017.4 1463.7 3430.4 839.8 16118.8 12402.9 26402.8 29515.8 18528.8 4509.8 912.4 5012.8 1663.2 665.7 -862.2 3634.7 11791.3 13803.1 30779.2 -1041.8 1528.9 -18.8 1256.8 -1720.9 17075.6 162.7 2144.6
MEQ -2124.4 949.3 2242.4 64.4 853.4 5993.6 10513.8 310.9 4790.3 1837.4 1849.3 1700.5 1016.8 33263.3 17685.4 9372.8 13225.9 15470.0 14826.1 1461.8 569.2 4515.9 2899.0 257.3 -2883.2 7867.2 861.3 -279.1 1099.7 7238.4 2954.4 -84.3 3116.5 10837.1 6219.6 994.6 1391.5
BZLF1 -2770.5 -769.1 -4329.3 -4146.8 -1388.7 379.9 2380.1 -1833.6 -2351.9 1376.9 -326.9 1404.2 -618.6 -779.3 -2752.1 -1963.9 -271.1 -384.6 -520.4 -1860.7 -202.9 -961.0 -785.6 -280.1 -2085.9 -1992.5 -235.0 -705.2 122.9 -446.6 -2773.1 -448.3 -1377.4 -2226.8 -2414.6 9824.6 886.0
K-bZIP -2506.1 -261.5 -1129.1 -1520.8 -1119.4 90.3 1383.8 -83.6 659.2 693.1 -100.8 1560.6 -845.4 254.7 2668.3 1509.1 -551.4 -126.1 -83.1 431.1 15.5 -102.3 -661.8 361.0 -382.6 -865.0 -391.5 -602.8 285.6 -1003.9 -634.6 -734.2 -95.6 -515.6 -627.4 1041.9 12707.8
MEQ1800 MEQ625 MEQ125 MEQ25 MEQ5 MEQ1 HBZ1800 HBZ625 HBZ125 HBZ25 HBZ5 HBZ1 BZLF1 BZLF1CT anti-MEQ anti-MEQ2000anti-MEQ1000 anti-MEQ500 MEQ ATF2 JUN BATF3
CEBPA -1956.4 -1048.8 -1137.8 -41.9 6.6 11.7 2384.8 1231.9 -637.9 -104.5 3.9 9.2 CEBPA -918.0 -541.4 CEBPA -343.6 -981.7 -798.0 -1089.6 -1860.5 -1209.5 -220.3 2169.7
CEBPB 2477.9 1657.6 -257.4 -7.1 23.5 25.1 849.8 -179.6 -826.4 -106.7 15.1 26.2 CEBPB -1035.4 -215.1 CEBPB -235.4 -520.4 -551.9 -195.6 -3720.1 -2318.1 -543.4 2156.1
CEBPD 303.1 130.4 -549.8 -36.6 8.0 11.9 -3249.3 -4236.0 -1639.3 -215.2 -5.9 1.3 CEBPD -1303.9 -654.4 CEBPD -502.5 -1077.4 -1297.4 -771.9 -2151.3 -3235.8 -540.0 2625.6
CEBPG 650.2 -220.2 -551.7 -19.9 9.4 14.6 36408.3 27983.8 6476.6 180.3 12.9 19.0 CEBPG -1356.1 -554.1 CEBPG 1982.6 1989.1 1100.7 509.0 -658.6 5155.8 345.5 5172.2
DDIT3 18879.9 14831.1 3871.3 148.0 55.4 30.9 7672.1 8868.3 1329.4 -41.3 -1.9 7.2 DDIT3 -673.9 -471.4 ATF1 -211.4 -924.7 -499.9 -85.8 609.1 -1961.5 -947.1 -2072.6
ATF1 7006.1 2915.6 -52.6 -0.3 23.6 24.3 10475.4 4560.9 115.9 -42.6 17.1 31.0 ATF1 -1020.0 -127.6 CREB1 -3510.3 -4096.5 -1946.2 -740.8 535.5 -6256.7 -1354.7 -3906.8
CREB1 6904.3 2468.8 -110.8 -3.6 67.1 74.4 13052.6 3906.6 -547.1 -149.2 45.4 66.3 CREB1 -1711.8 -347.5 CREB3L3 -48.9 -808.8 -836.8 -345.1 -2395.3 -933.4 -830.6 -375.9
CREB3L3 -1350.9 -1580.8 -1121.0 -37.2 4.8 6.9 -2274.8 -3930.3 -1141.3 -101.8 -0.9 7.1 CREB3L3 -1068.1 -575.7 CREB3 -319.6 -1159.1 -1048.7 -580.3 -1330.6 -820.6 -279.0 438.1
CREB3 -132.6 -970.8 -359.2 -42.2 14.3 17.3 -1840.8 -1762.8 -1190.9 -71.9 6.6 16.1 CREB3 -905.4 -114.4 ATF6 -751.9 -2121.8 -2701.0 -771.7 -1940.4 -3780.2 -1124.3 -2020.6
ATF6 -2339.8 -2589.6 -1057.9 -43.7 9.1 20.0 -8566.8 -4360.4 -2222.2 -227.2 -29.6 -1.6 ATF6 -826.5 -62.1 CREBZF 698.6 1197.8 769.6 510.6 2290.8 -789.8 296.4 1020.3
CREBZF 606.3 629.6 -69.9 -19.4 21.9 23.9 44116.1 43809.8 18047.3 742.3 124.8 87.2 CREBZF -884.4 -232.1 XBP1 -2030.7 -2413.3 -2652.4 -1757.5 -3871.8 -2048.6 -359.3 -1979.3
XBP1 -2754.9 -2262.8 -954.5 -29.9 4.6 12.1 -3006.0 -5468.3 -3432.9 -202.6 -3.3 -0.8 XBP1 -434.5 -29.5 HLF -199.3 -605.1 -873.8 -71.1 -3105.3 -2699.3 -188.0 121.6
HLF -1104.4 -552.6 -850.5 -33.6 2.9 12.9 -1963.8 -1077.0 -1917.5 -149.6 11.9 0.4 HLF -553.8 225.8 NFIL3 -431.0 -878.9 -1388.9 -372.2 16377.4 -1942.6 -513.1 305.7
NFIL3 34569.3 25897.4 9320.6 500.5 132.3 53.6 -787.4 -3668.9 -2195.8 -241.9 -18.3 5.9 NFIL3 -56.1 -321.1 ATF2 15474.9 29845.1 18609.9 10084.3 29036.9 6994.6 4898.9 5202.8
ATF2 43809.1 34865.6 11030.8 489.5 164.9 54.7 49945.8 37822.1 7240.8 267.3 39.1 39.6 ATF2 -1065.1 -220.6 ATF7 18632.6 27526.6 17875.0 12471.2 22867.0 9594.1 8099.6 7512.3
ATF7 33504.2 27277.8 10417.8 650.5 176.5 67.6 48362.3 49724.4 17226.0 1250.1 166.1 93.2 ATF7 -656.3 -103.8 JUN 4410.5 7446.3 5109.8 3051.3 33011.3 14760.4 1997.3 11768.7
JUN 40956.9 35828.9 19746.9 1562.1 441.8 138.4 46284.6 48346.8 33404.8 4710.6 608.9 271.3 JUN -1086.8 -451.1 JUNB 1590.3 3779.5 2474.8 1351.5 29327.3 4758.5 449.4 9728.8
JUNB 38247.8 34017.6 14665.1 814.4 240.6 67.4 46897.5 49292.6 30957.0 2334.3 256.9 125.4 JUNB -1094.2 -177.3 JUND 1680.8 6417.1 3982.6 1944.3 34845.1 9823.1 788.6 11304.0
JUND 37200.4 35001.7 16522.2 1067.8 289.7 85.9 43240.8 45898.1 26671.4 2186.6 262.9 122.8 JUND -985.3 -473.9 FOS 237.5 -58.9 246.1 365.3 1014.5 13984.2 35014.5 703.8
FOS 1533.3 1001.4 -315.8 -2.3 22.0 19.3 -1246.9 -806.4 -476.1 -65.4 10.9 16.6 FOS -472.6 16.3 FOSL2 -797.3 -78.6 -1304.8 -2507.3 -894.6 9788.4 19126.3 266.4
FOSL2 2431.9 462.6 -4.6 7.8 17.2 21.2 -1947.4 -3642.8 -1629.8 -159.0 10.4 11.8 FOSL2 -352.9 -25.4 ATF3 985.6 2340.3 1654.7 949.5 11393.0 19928.4 12049.6 13952.3
ATF3 26154.6 16520.2 3833.8 174.4 75.2 51.3 28222.4 15280.8 1322.2 35.1 40.9 43.4 ATF3 -1700.5 -290.6 ATF4 584.3 5432.9 1864.5 1157.2 3546.8 1728.8 -1060.4 14458.4
ATF4 9900.7 4689.4 827.6 27.8 27.3 25.0 1286.8 -1658.2 -1008.5 -108.5 15.8 22.3 ATF4 -1323.3 -101.4 ATF5 -1081.3 -1536.0 -2095.3 -1318.5 -3394.4 -4831.8 -1941.1 3954.8
ATF5 -3566.5 -2411.4 -1035.8 -20.2 29.5 40.8 -4428.8 -1554.4 -853.5 -83.6 33.9 39.9 ATF5 -1965.4 -703.5 BATF 1095.1 950.3 811.1 -247.8 -5102.5 2149.7 13378.4 2425.2
BATF -3492.7 -3787.8 -1855.7 -114.3 -13.1 2.6 882.6 -3269.1 -2850.0 -261.4 -22.4 -18.2 BATF -716.5 -279.3 BATF3 3505.8 7043.8 3208.4 1636.4 7014.1 9068.7 12668.4 5699.1
BATF3 19417.1 14058.3 4411.0 219.3 80.8 41.4 5455.3 65.9 -454.7 -120.3 3.9 26.9 BATF3 -532.1 -396.4 MAFG 434.1 -71.2 -514.9 -44.6 476.1 -253.8 268.3 2433.0
MAFG 3525.3 984.3 -9.8 -21.8 15.9 16.0 43349.9 36152.3 11382.6 401.1 54.8 43.5 MAFG 104.1 521.1 MAF -597.1 -1622.8 -869.6 -473.8 -2118.5 -253.3 92.8 -1080.9
MAF -2530.1 -1860.8 -1105.5 -20.2 5.8 12.3 32799.1 28090.8 10693.6 816.9 104.6 51.8 MAF -355.6 -199.3 MAFB 59.5 -1223.2 -483.7 -469.0 -2231.4 -733.8 -217.7 -935.9
MAFB -2983.1 -3317.3 -1134.9 -45.6 7.9 17.4 45207.9 33537.3 9535.5 349.5 42.8 53.8 MAFB -701.6 -67.6 NFE2 -754.6 -1774.4 -1274.8 -1921.6 -327.3 -2474.9 -544.6 -1826.8
NFE2 6121.4 3238.4 272.9 23.5 19.1 16.3 -2244.5 -3426.1 -1732.3 -145.9 -13.4 5.9 NFE2 -381.4 -608.1 NFE2L1 -784.6 -2374.6 -2141.1 -1102.9 -2314.9 98.8 -284.6 -769.6
NFE2L1 -625.6 -1323.4 -740.9 -30.4 6.6 13.6 -4047.9 -1621.0 -1401.2 -66.3 5.0 11.4 NFE2L1 -402.0 -371.4 NFE2L3 -486.8 -1242.3 -816.4 -297.1 -2088.4 -4486.5 -1628.7 -3341.4
NFE2L3 -3538.4 -3732.2 -1775.9 -93.2 4.6 19.9 -4985.8 -5444.1 -2290.4 -204.6 -6.1 22.6 NFE2L3 -2073.9 -552.9 BACH1 86.9 -1658.8 -247.4 -25.9 3391.9 6185.9 456.6 895.5
BACH1 7620.1 4622.3 101.1 3.7 37.4 36.1 -3649.9 -2560.1 -1027.5 -132.0 8.4 27.5 BACH1 -545.3 -451.0 MEQ 29778.6 28393.8 23575.5 19969.3 3605.4 18790.1 11986.9 4714.5
HBZ 16059.6 14584.4 5662.5 382.9 120.4 51.4 -657.0 74.8 -461.1 -42.8 9.1 12.3 BZLF1 3400.1 1743.3 anti-MEQ -109.4 -1402.1 -1635.9 -764.9 30928.2 23309.9 4148.3 2632.5
MEQ 12345.1 7763.5 2379.4 83.4 38.2 24.3 25434.4 23555.3 7755.9 406.1 55.3 35.4 BZLF1CT 8831.0 7053.4
